Abstract
The peptidic nature of anti-IAPs N-terminus Smac-derived peptides precludes their utilization as potential therapeutic anticancer agents. Recent advances in the development of novel Smacderived peptidomimetics and non-peptidic molecules with improved anti-IAPs activity and resistance to proteolytic cleavage have been reported and led to a number of candidates that are currently in clinical trials including LCL-161, SM-406/AT-406, GDC-0512/GDC-0917, and birinapant. As an attempt to improve the proteolytic stability of Smac peptides, we developed the Aza-peptide AzaAla- Val-Pro-Phe-Tyr-NH2 (2). Unlike unmodified peptide Ala-Val-Pro-Phe-Tyr-NH2 (1), analogue (2) exhibited resistance towards proteolytic cleavage by two aminopeptidases; LAP and DPP-IV, while retaining its IAP inhibitory activity. This was due to the altered planar geometry of the P1 residue side chain. Our findings showed that using aza-isosteres of bioactive peptide sequences imbue the residue with imperviousness to proteolysis; underscoring a potential approach for developing a new generation of Smac-derived Aza-peptidomimetics.
Keywords: Aminopeptidases, Apoptosis, Aza-peptides, Caspase 9, IAPs, Smac.
Protein & Peptide Letters
Title:Smac-Derived Aza-Peptide As an Aminopeptidase-Resistant XIAP BIR3 Antagonist
Volume: 22 Issue: 9
Author(s): Mohamed A. Elsawy, Irina G. Tikhonova, Lorraine Martin and Brian Walker
Affiliation:
Keywords: Aminopeptidases, Apoptosis, Aza-peptides, Caspase 9, IAPs, Smac.
Abstract: The peptidic nature of anti-IAPs N-terminus Smac-derived peptides precludes their utilization as potential therapeutic anticancer agents. Recent advances in the development of novel Smacderived peptidomimetics and non-peptidic molecules with improved anti-IAPs activity and resistance to proteolytic cleavage have been reported and led to a number of candidates that are currently in clinical trials including LCL-161, SM-406/AT-406, GDC-0512/GDC-0917, and birinapant. As an attempt to improve the proteolytic stability of Smac peptides, we developed the Aza-peptide AzaAla- Val-Pro-Phe-Tyr-NH2 (2). Unlike unmodified peptide Ala-Val-Pro-Phe-Tyr-NH2 (1), analogue (2) exhibited resistance towards proteolytic cleavage by two aminopeptidases; LAP and DPP-IV, while retaining its IAP inhibitory activity. This was due to the altered planar geometry of the P1 residue side chain. Our findings showed that using aza-isosteres of bioactive peptide sequences imbue the residue with imperviousness to proteolysis; underscoring a potential approach for developing a new generation of Smac-derived Aza-peptidomimetics.
Export Options
About this article
Cite this article as:
Elsawy A. Mohamed, Tikhonova G. Irina, Martin Lorraine and Walker Brian, Smac-Derived Aza-Peptide As an Aminopeptidase-Resistant XIAP BIR3 Antagonist, Protein & Peptide Letters 2015; 22(9) . https://dx.doi.org/10.2174/0929866522666150622101626
DOI https://dx.doi.org/10.2174/0929866522666150622101626 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide for New Editors
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Recent Advances in Pretargeted Radioimmunotherapy
Current Medicinal Chemistry Resveratrol and Ischemic Preconditioning in the Brain
Current Medicinal Chemistry Anticancer Potential and Molecular Targets of Pristimerin: A Mini- Review
Current Cancer Drug Targets Cancer-Homing Toxins
Current Pharmaceutical Design Neuropathic Pain and Lung Delivery of Nanoparticulate Drugs: An Emerging Novel Therapeutic Strategy
CNS & Neurological Disorders - Drug Targets Advances in Synergistic Combinations of Chinese Herbal Medicine for the Treatment of Cancer
Current Cancer Drug Targets Current Insights into the Role of HIF-1 in Cutaneous Wound Healing
Current Molecular Medicine Inflammation and Antiangiogenesis in Cancer
Current Medicinal Chemistry Nano-pharmaceutical Formulations for Targeted Drug Delivery against HER2 in Breast Cancer
Current Cancer Drug Targets Imaging Findings of Primary Non-functioning Hepatic Paraganglioma: A Case Report
Current Medical Imaging New Perspectives in Glioma Immunotherapy
Current Pharmaceutical Design Realizing the Potential of Blueberry as Natural Inhibitor of Metastasis and Powerful Apoptosis Inducer: Tapping the Treasure Trove for Effective Regulation of Cell Signaling Pathways
Anti-Cancer Agents in Medicinal Chemistry Heavy Metals and Epigenetic Alterations in Brain Tumors
Current Genomics Development of Novel, Highly Cytotoxic Fusion Constructs Containing Granzyme B: Unique Mechanisms and Functions
Current Pharmaceutical Design Poxvirus Cancer Therapy
Recent Patents on Anti-Infective Drug Discovery When Neighbors Talk: Colon Cancer Cell Invasion and Tumor Microenvironment Myofibroblasts
Current Drug Targets Angiogenesis Inhibitors: Implications for Combination with Conventional Therapies
Current Pharmaceutical Design Targeting the Cancer-Stroma Interaction: A Potential Approach for Pancreatic Cancer Treatment
Current Pharmaceutical Design Pharmacodynamics of Radiolabelled Anticancer Drugs for Positron Emission Tomography
Current Pharmaceutical Design MYC as Therapeutic Target for Embryonal Tumors: Potential and Challenges
Current Cancer Drug Targets